Relationship between microRNA-146a expression and plasma renalase levels in hemodialyzed patients

Dziedzic, Marcin; Powrózek, Tomasz; Orłowska, Ewelina; Koch, Wojciech; Kukuła-Koch, Wirginia; Gaweł, Kinga; Bednarek-Skublewska, Anna; Małecka‐Massalska, Teresa; Milanowski, Janusz; Petkowicz, Beata; Solski, Janusz

doi:10.1371/journal.pone.0179218

Cited by 7 publications

(5 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…investigated the correlation between plasma renalase concentration and miR-146a-5p expression in hemodialysis patients. Patients with simultaneous low miR-146a expression and high level of renalase were found to have a significantly longer survival time compared with other patients, and both miRNA-146a and renalase levels were estimated as independent prognostic factors of hemodialyzed patients' survival time32. Micro RNA 146 has been shown to be involved in the regulation and control of inflammatory processes.…”

Section: Discussionmentioning

confidence: 99%

Micro RNA 146a-5p expression in Kidney transplant recipients with delayed graft function

et al. 2019

View full text Add to dashboard Cite

Introduction: The development of novel non-invasive biomarkers of kidney graft dysfunction, especially in the course of the delayed graft function period would be an important step forward in the clinical practice of kidney transplantation. Methods: We evaluated by RT-PCR the expression of miRNA-146 to -5p ribonucleic micro-acids (miRNAs) in the peripheral blood and renal tissue obtained from kidney transplant recipients who underwent a surveillance graft biopsy during the period of delayed graft function. Results: In biopsy samples, the expression of miR-146a-5p was significantly increased in the group of patients with delayed graft function (DGF) (n = 33) versus stables patients (STA) (n = 13) and patients with acute rejection (AR) (n = 9) (p = 0.008). In peripheral blood samples, a non-significant increase of miR-146a-5p expression was found in the DGF group versus STA and AR groups (p = 0.083). No significant correlation was found between levels of expression in biopsy and plasma. ROC curve analysis revealed an AUC of 0.75 (95% CI: 0.62-0.88) for the renal tissue expression and 0.67 (95% CI 0.52-0.81) for the peripheral blood expression. Conclusion: We conclude that miR-146a-5p expression has a distinct pattern in the renal tissue and perhaps in the peripheral blood in the setting of DGF. Further refinements and strategies for studies should be developed in the field of non-invasive molecular diagnosis of kidney graft dysfunction.

show abstract

Section: Discussionmentioning

confidence: 99%

Micro RNA 146a-5p expression in Kidney transplant recipients with delayed graft function

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Furthermore, miR-146a rs2910164 has been reported to be associated with Preeclampsia in Gestational Diabetes in the Egyptian population [68]. It is suggested that the expression of miR-146a is correlated with the levels of plasma renalase enzyme that maintains renal blood pressure [68][69][70].…”

Section: Mir-146a Rs2910164 C>gmentioning

confidence: 99%

Potential Impact of MicroRNA Gene Polymorphisms in the Pathogenesis of Diabetes and Atherosclerotic Cardiovascular Disease

Elfaki

Mir

et al. 2019

JPM

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are endogenous, small (18–23 nucleotides), non-coding RNA molecules. They regulate the posttranscriptional expression of their target genes. MiRNAs control vital physiological processes such as metabolism, development, differentiation, cell cycle and apoptosis. The control of the gene expression by miRNAs requires efficient binding between the miRNA and their target mRNAs. Genome-wide association studies (GWASs) have suggested the association of single-nucleotide polymorphisms (SNPs) with certain diseases in various populations. Gene polymorphisms of miRNA target sites have been implicated in diseases such as cancers, diabetes, cardiovascular and Parkinson’s disease. Likewise, gene polymorphisms of miRNAs have been reported to be associated with diseases. In this review, we discuss the SNPs in miRNA genes that have been associated with diabetes and atherosclerotic cardiovascular disease in different populations. We also discuss briefly the potential underlining mechanisms through which these SNPs increase the risk of developing these diseases.

show abstract

“…Finally, renalase can hinder inflammasome activation and the release of IL-1β [ 32 , 44 , 62 ]. Taken together, renalase favors significant cytoprotection related to inflammation, oxidative stress, and apoptosis [ 28 , 29 , 30 , 31 , 32 , 37 , 38 , 39 , 50 , 59 , 62 ], whereby recent research also discloses its potential in diverse cardiac [ 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 ] and kidney pathologies [ 75 , 76 , 77 , 78 ] and in the pathophysiology of COVID-19 [ 79 , 80 ]. It will be captivating to conduct future scrutiny toward an excellent comprehension of renalase pleiotropy.…”

Section: The Molecular Signature Of Renalasementioning

confidence: 99%

The Multi-Faceted Nature of Renalase for Mitochondrial Dysfunction Improvement in Cardiac Disease

Stojanović

Milenković

et al. 2023

Cells

View full text Add to dashboard Cite

The cellular mechanisms and signaling network that guide the cardiac disease pathophysiology are inextricably intertwined, which explains the current scarcity of effective therapy and to date remains the greatest challenge in state-of-the-art cardiovascular medicine. Accordingly, a novel concept has emerged in which cardiomyocytes are the centerpiece of therapeutic targeting, with dysregulated mitochondria as a critical point of intervention. Mitochondrial dysfunction pluralism seeks a multi-faceted molecule, such as renalase, to simultaneously combat the pathophysiologic heterogeneity of mitochondria-induced cardiomyocyte injury. This review provides some original perspectives and, for the first time, discusses the functionality spectrum of renalase for mitochondrial dysfunction improvement within cardiac disease, including its ability to preserve mitochondrial integrity and dynamics by suppressing mitochondrial ΔΨm collapse; overall ATP content amelioration; a rise of mtDNA copy numbers; upregulation of mitochondrial genes involved in oxidative phosphorylation and cellular vitality promotion; mitochondrial fission inhibition; NAD+ supplementation; sirtuin upregulation; and anti-oxidant, anti-apoptotic, and anti-inflammatory traits. If verified that renalase, due to its multi-faceted nature, behaves like the “guardian of mitochondria” by thwarting pernicious mitochondrial dysfunction effects and exerting therapeutic potential to target mitochondrial abnormalities in failing hearts, it may provide large-scale benefits for cardiac disease patients, regardless of the underlying causes.

show abstract

Relationship between microRNA-146a expression and plasma renalase levels in hemodialyzed patients

Cited by 7 publications

References 51 publications

Micro RNA 146a-5p expression in Kidney transplant recipients with delayed graft function

Micro RNA 146a-5p expression in Kidney transplant recipients with delayed graft function

Potential Impact of MicroRNA Gene Polymorphisms in the Pathogenesis of Diabetes and Atherosclerotic Cardiovascular Disease

The Multi-Faceted Nature of Renalase for Mitochondrial Dysfunction Improvement in Cardiac Disease

Contact Info

Product

Resources

About